If You Invested in Ideaya Biosciences (IDYA)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapies for cancer. The company describes itself as committed to developing transformative therapies for molecularly defined solid tumor indications, using a precision oncology approach that aligns drug mechanisms with the genetic drivers of disease.

IDEAYA emphasizes expertise in small-molecule drug discovery, structural biology, and bioinformatics, combined with internal capabilities in identifying and validating translational biomarkers. These capabilities are used to develop tailored, potentially first-in-class targeted therapies for specific patient populations. The company highlights a deep pipeline of product candidates centered on synthetic lethality and antibody-drug conjugates (ADCs) for solid tumors.

Core Focus in Precision Oncology

According to multiple company disclosures, IDEAYA's mission is to bring forward a new wave of precision oncology therapies that are more selective, more effective, and highly personalized, with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. Its approach relies on matching targeted agents and ADCs to tumors defined by biomarkers, genetic alterations, or specific protein expression patterns.

The company reports that it is advancing a broad pipeline that includes:

• Darovasertib, an investigational oral protein kinase C (PKC) inhibitor being developed for uveal melanoma (UM), including metastatic uveal melanoma (mUM) and primary UM in neoadjuvant and adjuvant settings.
• IDE397, a potential first-in-class small molecule inhibitor of MAT2A, being evaluated in combination with the Trop2-directed ADC Trodelvy in MTAP-deleted urothelial cancer and explored in MTAP-deleted non-small cell lung cancer (NSCLC).
• IDE849, a DLL3-targeting TOP1 ADC (also referenced as SHR-4849) for small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NEC), with clinical data reported from a Phase 1 trial conducted by partner Hengrui.
• IDE161, a potential first-in-class small molecule PARG inhibitor in Phase 1 dose optimization, intended to support combination strategies with TOP1 ADCs such as IDE849 and other TOP1i-based ADCs.
• IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, with an FDA-cleared IND for a Phase 1 trial in solid tumors known to express B7H3 and PTK7, including lung, colorectal, head and neck, and ovarian/gynecological cancers.
• IDE574, a potential first-in-class KAT6/7 dual inhibitor, with an IND submitted and later cleared to support a Phase 1 dose escalation trial in patients with solid tumors such as hormone receptor-positive breast cancer and lung adenocarcinoma.
• IDE892, a potential MTA-cooperative PRMT5 inhibitor for MTAP-deleted lung cancer and other MTAP-deleted solid tumors, with IND clearance to begin Phase 1 monotherapy dose escalation.

IDEAYA also references Werner Helicase (IDE275/GSK959) and Pol Theta Helicase (IDE705/GSK101) programs, which were previously under a collaboration and license agreement with GlaxoSmithKline. An 8-K filed in December 2025 notes that GSK elected to terminate the collaboration agreement, and the Werner Helicase and Pol Theta clinical programs are to be transferred back to IDEAYA, after which the company plans to evaluate strategic options for these programs.

Key Therapeutic Areas and Indications

The company’s public statements identify several priority cancer indications and molecularly defined settings:

• Uveal melanoma (UM), including primary UM and metastatic uveal melanoma (mUM). IDEAYA is conducting clinical trials of darovasertib as a neoadjuvant therapy in primary UM (OptimUM-09 and Phase 3 OptimUM-10) and in combination with crizotinib in first-line HLA*A2-negative mUM (Phase 2/3 OptimUM-02). The company has also discussed adjuvant development plans in collaboration with Servier.
• MTAP-deleted solid tumors, including urothelial cancer and NSCLC, through IDE397 and IDE892-based synthetic lethality strategies.
• Small cell lung cancer (SCLC) and other DLL3-overexpressing neuroendocrine tumors, through IDE849.
• B7H3/PTK7 co-expressing solid tumors, including lung, colorectal, and head and neck cancers, as well as ovarian/gynecological cancers, through IDE034.
• Breast and lung cancers characterized by lineage-specific transcription factor dependencies, through IDE574.

In a business update, IDEAYA highlighted that its pipeline is designed to address multiple indications with high unmet need, including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted lung, pancreatic, and urothelial cancers.

Pipeline Strategy and Synthetic Lethality

IDEAYA repeatedly describes its pipeline as focused on synthetic lethality and ADCs. Synthetic lethality approaches aim to exploit specific genetic alterations in tumors, such as MTAP deletions, by targeting complementary pathways like MAT2A or PRMT5. The company’s ADC programs, including IDE849 and IDE034, are designed to deliver TOP1 inhibitor payloads to tumors expressing targets such as DLL3, B7H3, and PTK7.

The company has also articulated a strategy of combining ADCs with DNA damage response (DDR) inhibitors, particularly PARG inhibition via IDE161, to potentially enhance the durability of response to TOP1 payload-based ADC therapies. This combination rationale is discussed in connection with IDE034 and IDE161, and with future combination plans for IDE849 and IDE161.

Collaborations and Licensing

IDEAYA has disclosed several key partnerships and licensing arrangements:

• An exclusive license agreement with Servier granting Servier rights to develop and commercialize darovasertib outside the United States. Under this agreement, IDEAYA received an upfront payment and is eligible for development, regulatory, and commercial milestone payments, as well as royalties on net sales outside the U.S. IDEAYA retains U.S. rights and collaborates with Servier on global development.
• A clinical trial collaboration and supply agreement with Pfizer to evaluate darovasertib in combination with crizotinib in metastatic uveal melanoma, under which Pfizer has provided defined quantities of crizotinib.
• A license arrangement with Jiangsu Hengrui Pharmaceuticals (Hengrui) related to IDE849 (also referred to as SHR-4849), under which Hengrui has conducted a Phase 1 trial in SCLC and NEC and presented data at the IASLC World Conference on Lung Cancer.
• A licensed program from Biocytogen for IDE034, a bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and licensed to IDEAYA. Biocytogen has described this as a first-in-class bispecific ADC project licensed to IDEAYA.

These collaborations support IDEAYA’s strategy of expanding its precision oncology pipeline and accessing external technologies, such as bispecific ADC platforms, while sharing development responsibilities and costs in certain programs.

Regulatory Designations and Clinical Development

Darovasertib has received multiple regulatory designations from the U.S. Food and Drug Administration (FDA), as reported by the company. These include Breakthrough Therapy Designation as neoadjuvant therapy in enucleation-recommended primary uveal melanoma, Fast Track designation for darovasertib in combination with crizotinib in adult patients with metastatic UM, and Orphan Drug designation in UM, including metastatic UM.

IDEAYA is conducting or planning several registration-enabling and Phase 3 trials involving darovasertib in both metastatic and primary uveal melanoma settings. The company has also outlined plans to advance multiple clinical-stage programs, including IDE849, IDE034, IDE161, IDE397, IDE892, and IDE574, across various solid tumor indications.

Exchange Listing and Sector Classification

IDEAYA Biosciences, Inc. is listed on The Nasdaq Global Select Market under the ticker symbol IDYA. In the context of industry classification, the company is described as a precision medicine oncology company, and in the provided data it is associated with Research and Development in Biotechnology within the broader Professional, Scientific, and Technical Services sector.

Use of Biomarkers and Molecular Diagnostics

Across its public communications, IDEAYA emphasizes the use of molecular diagnostics and translational biomarkers to select patient populations most likely to benefit from its therapies. This includes selecting patients based on genetic alterations such as MTAP deletion, protein expression of DLL3, B7H3, or PTK7, and specific disease subtypes like uveal melanoma or hormone receptor-positive breast cancer. The company states that it integrates biomarker discovery and validation into its drug development process to align therapies with the genetic and molecular features of tumors.

Positioning Within Oncology

IDEAYA positions itself as a precision oncology company with a deep pipeline of targeted agents and ADCs for solid tumors. Its programs span early-stage discovery through late-stage clinical development, with a particular emphasis on uveal melanoma, MTAP-deleted cancers, SCLC, neuroendocrine tumors, and other solid tumors defined by biomarker expression. The company’s disclosures indicate an intention to build combinations that connect ADC payload mechanisms with DNA damage response modulation, and to pursue synthetic lethality strategies in genetically defined tumor subsets.